Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Sophia Genetics S.A.. (4/8/13). "Press Release: Sophia Genetics Raises CHF 2,800,000 (Series A)".

Organisation Organisation Sophia Genetics S.A.
  Group Sophia Genetics (Group)
Products Product genomic software tools
  Product 2 oncology
Index term Index term Sophia Genetics–SEVERAL: investment, 201304 financing round Series A CHF2.8m from private investors
Person Person Camblong, Jurgi (Sophia Genetics 201407 CEO + Co-Founder)

Sophia Genetics raises CHF 2.8 million with private investors in order to expand its commercial activities in several European countries and accelerate the development of its bioinformatic platform, dropGen™. Within the development, new functionalities are added to the bioinformatic tool to increase its performance in other applications with strong development potential, such as somatic genetics of tumours and cardiogenetics.

"This first Series A financing is a logical next step after our seed funding of Euros 653'000 in 2012 and once again brings together private investors. With the economic crisis, investors are looking to diversify their positions outside traditional paths such as banks or investment funds. They are placing their bets on high value-added sectors such as bioinformatics, where they can expect a high return on investment in the mid-term"

Dr Jurgi Camblong, CEO of Sophia Genetics, interviewed by Biotech Finances, 6 May 2013.

Record changed: 2019-06-11


Picture [LSA] – The Business Web Portal 650x89px

More documents for Sophia Genetics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top